Navigation Links
Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
Date:11/21/2008

TISENILIN(R) monoclonal antibody platform in Europe that adds to our reach in our licensing programs because the patent increases the number of countries that will be covered by our current and future licensing agreements. We obtained validation of the patent in several European countries and anticipate doing so in more than 20 countries by the end of this year. At least 6 million Europeans suffer from AD, representing the second largest market after the United States. In addition to Europe, our patent has issued in Japan, China, Australia and New Zealand. We continue to advance our application for a patent in the United States.

  • Since our inception, we have obtained important new patents related to each of our technology platforms, including the validation in Europe of patents related to our clinical candidate OXIGON(R) covering multiple disease indications, and our AD vaccine technology, RECALL-VAX(TM). In addition, we continue to file patent applications to increase the strength of our patent estate and value in the market.

2. Identify and develop Intellect's product pipeline:

  • Our most advanced product candidate that has come from our ANTISENILIN(R) monoclonal antibody technology platform is a humanized antibody, named IN-N01, for the treatment of Alzheimer's disease. Over the past several months we have successfully completed "humanization", a process that is required in order to adapt the antibody to human use. We believe that our antibody has the potential to be "best-in-class", based on its unique design and engineering. At the appropriate stage of this product candidate's development, we will select a pharmaceutical partner with which to advance its development. Various companies have started to show interest already.

  • We completed Phase
    '/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
4. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
5. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
6. Amarin Secures Global Intellectual Property Rights for Lipid Programs
7. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
8. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
9. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease
10. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
11. IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... SonaCare Medical, a leading manufacturer of ... participated in the American Urology Association’s (AUA) surgical ... opinion leaders in urology presented on the latest ... masses while attendees had the opportunity to evaluate ... labs. Attendees at the Los Angeles, CA lab, ...
(Date:11/26/2014)... 25, 2014 The Pittcon marketing department ... conference and exposition mobile app, Pittcon ... in the App Store for iOS and Android devices ... tool before, during and after the event. It acts ... exhibiting companies, technical sessions, Conferee Networking sessions and short ...
(Date:11/26/2014)... Boston, MA (PRWEB) November 26, 2014 ... and collaboration company is proud to announce that Darren ... Development and Sales. Darren will drive the ... and positive customer experience. , Darren brings ... He has held key roles in channel operations, from ...
(Date:11/26/2014)... 2014 Theravalues Corporation est fier d,annoncer ... européen au salon Hi Europe 2014 (du 2 ... Curcumine la plus biodisponible actuellement sur ... à des ingrédients approuvés par les règlements européens. ... présent dans la racine de curcuma ( Curcuma ...
Breaking Biology Technology:SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Pittcon Releases 2015 Mobile App 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3
... , , WARSAW, ... ZMH ; SWX: ZMH) today announced the launch of the new ... surgeons and subject matter experts to develop a unique model for ... Surgeon-to-Surgeon programs under one, consolidated service offering, the enhanced Zimmer Institute ...
... EL SEGUNDO, Calif., July 27 NASA has exercised a ... continuing support to the Space Life Sciences Directorate at NASA,s Johnson ... The work will be done by Wyle,s Integrated Science and ... the bioastronautics contract, Wyle,s work supports the International Space Station, space ...
... , SOUTH PLAINFIELD, N.J., July 27 ... Phase 2 clinical trial of PTC299 in adult patients with ... the development of non-malignant brain tumors. PTC299 is a ... selectively block tumor-related vascular endothelial growth factor (VEGF). With ...
Cached Biology Technology:Zimmer Launches New Medical Education and BioSkills Training Program 2Zimmer Launches New Medical Education and BioSkills Training Program 3Zimmer Launches New Medical Education and BioSkills Training Program 4NASA Extends Bioastronautics Contract With Wyle for Total Value of $976 Million 2PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 2PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 3PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 4
(Date:11/4/2014)... 2014 – University of Utah engineers developed the first ... fuel produce electricity without needing to ignite the fuel. ... portable electronics, off-grid power and sensors. , A study ... American Chemical Society journal ACS Catalysis . , ... reaction between a fuel and an oxygen-rich source such ...
(Date:11/4/2014)... newly published research study examining only marketing directed ... fast food restaurants has found that the majority ... exposed to such marketing tactics. , Authored by ... colleagues, the study is the first to examine ... and exterior of fast food restaurants and its ...
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... burn cleaner, a research report published in the January ... the food industry could take a similar approach toward ... additives would be based on work of Israeli researchers ... wine, fruits, and vegetables) simultaneously with high-fat foods may ...
... a higher prevalence of body abnormalities, such as asymmetric lower ... defect responsible for the abnormality may play a role in ... January 2 issue of JAMA. Certain genetic syndromes ... cancer development in children. Several studies have shown that developmental ...
... that doctors treating life-threatening emergencies such as allergy attacks may ... labelling. Adrenaline is stored in salt water in glass ... The amount of adrenaline contained in the ampoule is ... drug per 1 mL of salt water) and a ratio ...
Cached Biology News:Study examines genetic defects linked to body abnormalities in patients with childhood cancer 2Doctors may be giving the wrong dosage of adrenaline in an emergency because of labelling 2
Human PDGF, CF...
... utility and flexibility press-to-seal silicone isolators can ... the researcher. They are available either pre-cut ... material that can be easily trimmed to ... and non-cytotoxic and can be used to ...
... The mycobacteria in Complete Freund's ... the injection site which enhances the immuneresponse. ... is used for the initial injections; Incomplete ... boosts. Antigens (preferably in saline) are typically ...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
Biology Products: